SG3 Management’s AstraZeneca AZN Stock Holding History

SG3 Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,250	Closed	-$750K	–	961
2021 Q4	$728K	Sell	6,250 -44,800	-88%	-$5.27M	0.01%	547
2021 Q3	$6.13M	Buy	51,050 +37,300	+271%	+$4.34M	0.19%	112
2021 Q2	$1.65M	Buy	13,750 +11,250	+450%	+$1.23M	0.06%	358
2021 Q1	$249K	Buy	+2,500	New	+$251K	0.01%	926
2020 Q3	–	Sell	-7,000	Closed	-$740K	–	875
2020 Q2	$740K	Buy	+7,000	New	+$723K	0.05%	331

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

SG3 Management's AZN Position: Q1 2022 in Review

SG3 Management sold out of AstraZeneca (AZN) in Q1 2022, closing a stake of 6,250 shares — an estimated $750K sold.

SG3 Management first reported a position in AZN in Q2 2020 and held it in 5 quarters. The position peaked at $6.13M in Q3 2021. 982 funds tracked by Wall St. Rank hold AZN as of Q1 2022.

SG3 Management reported no remaining AstraZeneca position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 6,250 AstraZeneca shares in Q1 2022, an estimated $750K.
SG3 Management first reported a position in AstraZeneca in Q2 2020 and held it in 5 quarters.
SG3 Management's AstraZeneca position peaked at $6.13M in Q3 2021.
982 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.